



Briefs

June 1, 2004 By Staff

A small Italian study suggests that the protease inhibitor atazanavir (Reyataz) may work as a booster for some other PIs.

In a Belgian study, drug-resistant HIV lay dormant for five years, waiting to reemerge, in HAART-taking, undetectable HIVers.

Sculptra (a.k.a. New-Fill) has FDA advisory committee go-ahead to seek approval as treatment for HIV facial wasting.

4 percent of 165 HIVers in a French study developed kidney or gallstones-researchers traced the problems to Kaletra.

Sunshine may increase women's risk for HIVer-loving human papillomavirus (HPV) by suppressing their immune systems.

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.poz.com/article/Briefs-332-8606>